Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Financial Results

Every financial results filing by a US-listed company that our alert engine sent, newest first.

8:11 AM ET 8-K
Financial Results Rhythm Pharmaceuticals, Inc. RYTM

Rhythm Pharmaceuticals Financial Results

Rhythm Pharmaceuticals reported Q3 2026 net product revenue of $92.1 million, a 29% sequential increase driven by the strong U.S. launch of IMCIVREE for acquired hypothalamic obesity. The company also secured a five-year term loan facility for up to $750 million and announced plans to advance bivamelagon into pivotal development for Prader-Willi syndrome.

Term
Q3 2026

“Rhythm continues to make strong progress in bringing IMCIVREE® (setmelanotide) to patients with acquired hypothalamic obesity (HO), highlighted by continued commercial momentum in the United States. Our commercial launch in Japan represents another important milestone in a market with the potential to become our second largest.”

David Meeker, M.D., Chairman, Chief Executive Officer and President of Rhythm Pharmaceuticals

“We are excited about advancing our next-generation MC4R agonists, beginning with bivamelagon. Strong clinical results have reinforced our confidence in its potential across multiple indications, and we look forward to initiating pivotal trials in acquired HO and Prader-Willi syndrome.”

David Meeker, M.D., Chairman, Chief Executive Officer and President of Rhythm Pharmaceuticals
8:10 AM ET 8-K
Financial Results Nuveen Churchill Direct Lending Corp. NCDL

Nuveen Churchill Direct Lending Financial Results

Nuveen Churchill Direct Lending Corp. reported Q3 2026 net investment income of $0.38 per share and a net asset value of $17.13 per share. The company declared a Q4 distribution of $0.38 per share and highlighted the commencement of operations for its new Senior Loan Fund I joint venture.

Term
Q3 2026

“NCDL reported solid third quarter financial results, highlighting the overall strength and stability of our investment portfolio. Our credit metrics and fundamentals remain strong, reflecting our conservative underwriting approach, as well as our well-diversified portfolio across position sizing and industry concentrations.”

Ken Kencel, President and Chief Executive Officer

“We took meaningful actions to optimize and strengthen our balance sheet and capital structure in the third quarter, including a refinancing of one of our CLOs and the addition of $100 million of unsecured debt.”

Shai Vichness, Chief Financial Officer and Treasurer
8:10 AM ET 10-Q
Financial Results Faeth Therapeutics, Inc. FTH

Faeth Therapeutics Q3 2026 Results: Net Loss of $20.4M, Loss Widens

Faeth Therapeutics reported a significant net loss of $206.6 million for the nine months ended September 30, 2026, primarily driven by a $133.0 million charge for acquired in-process research and development. The company significantly strengthened its balance sheet during the period, ending with $174.8 million in cash and marketable securities following a private placement and acquisition.

Key figure
Net loss $20.4M
8:10 AM ET 8-K
Financial Results Xplr Infrastructure, LP XIFR

Xplr Infrastructure Financial Results

XPLR Infrastructure reported Q3 2026 net income of $51 million and adjusted EBITDA of $471 million. The company updated its 2026 outlook toward the lower end of previous ranges and introduced 2027 guidance, while noting the completion of 85% of its 2026 repowering projects.

Term
Q3 2026

“We delivered solid financial results in the third quarter while continuing to make progress across our key priorities. We have now completed approximately 85% of our planned 2026 repowerings. We also completed sales of approximately 400 megawatts of additional interconnection assets and rights to NextEra Energy Resources, demonstrating the optionality embedded within our portfolio and our ability to unlock incremental value and redeploy capital across the portfolio.”

Alan Liu, president and chief executive officer of XPLR Infrastructure

“In addition, we retired the remaining balance of our 2026 unsecured notes. Today, with greater clarity on our full-year outlook as we approach year-end, we are providing an updated view of our 2026 financial outlook within our existing guidance ranges. In addition, we are introducing our 2027 financial expectations. We believe the underlying characteristics of the business support a durable profile over the longer term, with 2028 FCFBG expected to be in line with 2027.”

Alan Liu, president and chief executive officer of XPLR Infrastructure
8:10 AM ET 8-K
Financial Results Arvinas, Inc. ARVN

Arvinas Financial Results

Arvinas reported third quarter 2026 financial results and provided a corporate update on its protein degrader pipeline, including the initiation of a Phase 1/2 trial for its HPK1 degrader ARV-6723. The company ended the quarter with $1.1 billion in cash and equivalents, which it expects will fund operations into 2028. Key upcoming milestones include Phase 1 data readouts for ARV-393, ARV-027, and ARV-6723 through 2027.

“We executed strongly during the quarter and are entering an important period of clinical milestones that we believe will demonstrate the promise of our clinical-stage protein degraders. We are prioritizing investments where emerging evidence supports our goal of creating transformative medicines for patients. The upcoming data from our BCL6, polyQ-AR, and HPK1 degraders will begin to define the opportunity for these programs to change the treatment landscape, and we are grateful to the patients, investigators, and employees whose commitment makes this progress possible.”

Randy Teel, Ph.D., President and Chief Executive Officer of Arvinas
8:10 AM ET 8-K
Financial Results Alkermes plc. ALKS

Alkermes Financial Results

Alkermes plc reported third quarter 2026 total revenues of $480.1 million, driven by solid performance in its proprietary product portfolio including VIVITROL and LUMRYZ. The company reported GAAP net income of $16.3 million and reaffirmed its full-year 2026 financial expectations while highlighting progress in its orexin development programs.

Term
3 months

“We delivered solid commercial and financial performance in the third quarter while continuing to advance our portfolio of orexin 2 receptor agonists in central disorders of hypersomnolence and other neuropsychiatric conditions.”

Blair Jackson, President and Chief Executive Officer
8:10 AM ET 8-K
Financial Results Columbus Mckinnon Corp CMCO

Columbus Mckinnon Financial Results

Columbus McKinnon reported Q2 fiscal 2027 results with net sales growing 107% to $539.3 million, primarily driven by the acquisition of Kito Crosby. Despite a net loss of $25.5 million due to integration expenses, the company increased its full-year guidance for sales, Adjusted EBITDA, and Adjusted EPS.

“Building on record orders and sales in the first quarter, our team delivered strong second quarter performance that exceeded expectations. Sequential revenue growth was supported by sustained strength in the Americas and bolstered by stronger than anticipated demand in both Asia and EMEA.”

David J. Wilson, President and Chief Executive Officer

“Our integration of Kito Crosby is progressing well, supported by agile execution and strong collaboration across the combined organization. With our initial integration priorities firmly underway, we are sharpening our focus on the longer-term initiatives that will unlock the potential of the combined business.”

David J. Wilson, President and Chief Executive Officer
8:10 AM ET 10-Q
Financial Results Precision Biosciences Inc DTIL

Precision Biosciences Q3 2026 Results: Net Loss of $7.59M, Loss Narrows

Precision BioSciences is a clinical-stage gene editing company focused on its ARCUS technology. As of October 29, 2026, the company had 27,935,719 shares of common stock outstanding and continues to report significant operating losses with a need for substantial additional funding to support its research and development programs.

Key figure
Net loss $7.59M
8:10 AM ET 8-K
Financial Results Madrigal Pharmaceuticals, Inc. MDGL

Madrigal Pharmaceuticals Financial Results

Madrigal Pharmaceuticals reported third-quarter 2026 financial results, highlighted by Rezdiffra net sales of $431.3 million and the achievement of its first quarter of profitability. The company also announced that Rezdiffra reached blockbuster status with year-to-date net sales of $1.1 billion and plans to initiate a new Phase 3 outcomes trial, MAESTRO-CSPH, in the first half of 2027.

“Madrigal delivered another strong quarter, driven by continued Rezdiffra demand, deepening prescriber adoption and accelerating market growth. Rezdiffra surpassed $1 billion in year-to-date net sales, achieving blockbuster status less than three years after launch, and we are still early in a rapidly growing market.”

Bill Sibold, Chief Executive Officer of Madrigal

“Madrigal’s next major opportunity is in well-compensated cirrhosis, or F4c, an urgent unmet need for patients. Our objective in F4c is clear: be first and best. Our ongoing MAESTRO-NASH OUTCOMES trial positions us to deliver the first approved therapy to patients with this advanced stage of MASH.”

Bill Sibold, Chief Executive Officer of Madrigal
8:10 AM ET 8-K
Financial Results UL Solutions Inc. ULS

UL Solutions Financial Results

UL Solutions reported third-quarter 2026 revenue of $823 million, representing 5.1% total growth and 7.0% organic growth driven by the Industrial and Consumer segments. Net income rose 10.4% to $117 million, while Adjusted EBITDA margin expanded 90 basis points to a record 28.6%. Based on strong performance, the company raised its full-year organic revenue growth outlook to approximately 6.5%.

Term
Q3 2026

“This quarter’s record revenue and excellent margin expansion reflect our strategic focus and investments aligned to the megatrends including the global energy transition and electrification of everything. We are at the forefront of innovation and work alongside our customers as increasingly digital, interconnected products and supply chains drive demand for our trusted services and software.”

Jennifer Scanlon, President and CEO

“Our third-quarter results reflect continued strong execution across the business. We achieved 7.0% organic revenue growth and expanded our Adjusted EBITDA margin to a record 28.6%, driven by broad-based demand, operating leverage and productivity gains.”

Ryan Robinson, Executive Vice President and Chief Financial Officer
8:10 AM ET 8-K
Financial Results Dynatrace, Inc. DT

Dynatrace Financial Results

Dynatrace reported Q2 fiscal 2027 results with total revenue growing 17% year-over-year to $580 million and ARR increasing 16% to $2.21 billion. Alongside the earnings, the company announced a new $1 billion share repurchase authorization and scheduled an Investor Day for February 2027.

“Our Q2 results reflect continued top-line growth and strong operational efficiency. As organizations increasingly deploy AI agents into production, the need for enterprise-grade observability and governance has never been greater. By bringing Arize together with the Dynatrace platform, we are extending our end-to-end capabilities across the AI lifecycle, from development through production, giving customers greater control over model reliability, application performance, and business outcomes.”

Rick McConnell, Chief Executive Officer

“Our robust cash generation enables us to fund our strategic growth priorities while returning substantial capital to shareholders. Expanding our share repurchase authorization by $1 billion underscores the strength of our balance sheet, our confidence in our long-term growth trajectory, and our commitment to thoughtful capital allocation.”

Jim Benson, Chief Financial Officer
8:09 AM ET 8-K
Financial Results Xometry, Inc. XMTR

Xometry Financial Results

Xometry reported record third quarter 2026 results, with total revenue increasing 40% year-over-year to $252 million, driven by 43% growth in its AI-native marketplace. The company achieved a significant milestone by surpassing a $1 billion revenue run rate and reaching positive net income of $1.9 million compared to a loss in the prior year period.

Term
Q3 2026

“Our key growth initiatives drove record results in the third quarter, with marketplace growth of 43% year-over-year, as we surpassed the $1 billion revenue run rate. We further improved our marketplace experience and continue to deepen enterprise engagement, driving record net buyer additions and increasing wallet share in larger accounts.”

Sanjeev Singh Sahni, CEO at Xometry

“Our record-setting Q3 performance demonstrates the compounding growth and operational efficiency of our marketplace, delivering both strong revenue expansion and margin improvement. Revenue growth remained robust at the 40% level for the second quarter in a row, alongside record marketplace gross margin of 36.0%.”

James Miln, CFO at Xometry
8:09 AM ET 8-K
Financial Results Versant Media Group, Inc. VSNT

Versant Media Group Financial Results

Versant Media Group reported Q3 2026 revenue of $1.59 billion and net income of $47 million, driven by double-digit Platforms revenue growth and strong network viewership. The company reaffirmed its full-year outlook and raised its Free Cash Flow forecast to exceed $1.2 billion while announcing an additional $100 million accelerated share repurchase program.

Term
Q3 2026

“Versant’s momentum continues, with audience growth and the completion of all planned pay television distribution renewals for the year, underscoring the value and enduring appeal of our brands.”

Mark Lazarus, Chief Executive Officer

“Our third quarter performance demonstrates the financial discipline and flexibility that underpins Versant’s strategy. We delivered strong Platforms revenue, continued operating efficiencies and significant cash flow.”

Anand Kini, Chief Financial Officer and Chief Operating Officer
8:09 AM ET 8-K
Financial Results Shopify Inc. SHOP

Shopify Financial Results

Shopify reported Q3 2026 financial results with revenue increasing 32% year-over-year to $3.74 billion and GMV reaching $119.1 billion. The company achieved a free cash flow margin of 22% and expects Q4 revenue to continue growing at a low-thirties percentage rate.

Term
Q3 2026

“Shopify is uncommonly good at operating in two realities at the same time: the world our merchants exist in today, and the one they are moving towards. Q3 is the perfect example. We powered $119 billion in GMV, while continuing to build commerce into every surface, every agent, and increasingly, everywhere.”

Harley Finkelstein, President of Shopify

“Delivering these results at our scale speaks to the strength of our model, our multiple growth drivers, and our expanding addressable market.”

Jeff Hoffmeister, Chief Financial Officer of Shopify
8:09 AM ET 10-Q
Financial Results Shopify Inc. SHOP

Shopify Q3 2026 Results: Net Income $462M, Up 75.0% YoY

Shopify reported strong growth for the third quarter of 2026, with total revenue increasing to $3.74 billion compared to $2.84 billion in the prior year, driven largely by Merchant Solutions. Net income for the nine months ended September 30, 2026, rose significantly to $1.38 billion from $488 million in 2025, reflecting improved operational efficiency and higher gross profits.

Key figure
Net income $462M · +75.0% YoY
8:09 AM ET 8-K
Financial Results Bowhead Specialty Holdings Inc. BOW

Bowhead Specialty Holdings Financial Results

Bowhead Specialty Holdings reported Q3 2026 financial results with gross written premiums increasing 10.8% to $256.4 million. The company achieved a net income of $12.9 million and an adjusted return on equity of 15.9%, driven by growth in its Baleen Specialty division and digital underwriting models.

Term
Q3 2026

“Our third quarter results reflect the continued execution of our strategy, with gross written premiums increasing almost 11%, adjusted net income growing 16%, and adjusted return on equity reaching 15.9% for the quarter. Our digital businesses grew to almost 9% of total gross written premiums, demonstrating that our complementary craft and digital underwriting models are working as intended and broadening our opportunities for disciplined premium growth across market cycles.”

Stephen Sills, Chief Executive Officer
8:09 AM ET 8-K
Financial Results Vital Farms, Inc. VITL

Vital Farms Financial Results

Vital Farms reported Q3 2026 net revenue of $182.2 million, an 8.4% year-over-year decrease but a 9.7% sequential improvement from the second quarter. The company reported a net loss of $6.5 million and updated its full-year 2026 revenue outlook to approximately $730 million while withdrawing its 2030 financial targets.

Term
Q3 2026

“Q3 represented a meaningful sequential improvement from Q2, consistent with our previously communicated expectation that Q2 would represent the trough in our financial performance. Net revenue and Adjusted EBITDA both improved sequentially, distribution expanded, we reached record dollar and volume share of the shell egg category, and we made progress reducing excess supply and lowering our cost structure.”

Russell Diez-Canseco, Vital Farms’ Executive Chairperson, President and CEO

“We achieved the distribution gains we expected, although some of that distribution came on shelf later than planned, and we are taking a more conservative view of its near-term velocity contribution. We are focused on building velocity across our expanded distribution base, adding distribution where it makes sense, bringing new households to the Vital Farms brand, and maintaining discipline across supply and costs.”

Russell Diez-Canseco, Vital Farms’ Executive Chairperson, President and CEO
8:09 AM ET 8-K
Financial Results First Watch Restaurant Group, Inc. FWRG

First Watch Restaurant Group Financial Results

First Watch Restaurant Group reported Q3 2026 financial results with total revenues increasing 10.7% to $349.9 million and net income rising to $4.8 million. The company opened 16 new system-wide restaurants during the quarter and raised its full-year 2026 Adjusted EBITDA outlook to approximately $136.0 million.

Term
Q3 2026

“Our third-quarter performance is another encouraging proof point for the strength of First Watch. We delivered on our top-line plan, grew same-restaurant sales against our toughest comparison of the year and increased total revenue by 10.7%, all while opening 16 system-wide restaurants across 11 states.”

Chris Tomasso, CEO and President of First Watch

“Our teams continue to execute at a high level, driving Adjusted EBITDA growth ahead of our expectations and giving us the confidence to raise our full-year 2026 Adjusted EBITDA outlook to the high end of our previous guidance range.”

Chris Tomasso, CEO and President of First Watch
8:09 AM ET 8-K
Financial Results Talen Energy Corp TLN

Talen Energy Financial Results

Talen Energy reported Q3 2026 GAAP net income of $138 million and Adjusted EBITDA of $669 million, driven by contributions from acquired assets and higher capacity revenues. The company introduced 2027 Adjusted EBITDA guidance of $2.5 billion to $2.85 billion and announced a $1.5 billion accelerated share repurchase program.

Term
Q3 2026

“Talen delivered $669 million of Adjusted EBITDA and $433 million of Adjusted Free Cash Flow in the third quarter. With nine months behind us, we are reaffirming the midpoint and are narrowing the range of our 2026 guidance. We are also introducing our 2027 guidance that reflects strong PJM fundamentals and a full year of contributions from our recently acquired assets.”

Mac McFarland, Talen Chief Executive Officer

“Share repurchases remain the benchmark against which we evaluate capital allocation. This quarter, we increased our share repurchase program to $3.0 billion, including a $1.5 billion accelerated share repurchase program. We have now repurchased more than one third of the shares outstanding at emergence.”

Terry Nutt, Talen President
8:09 AM ET 8-K
Financial Results Teva Pharmaceutical Industries Ltd TEVA

Teva Pharmaceutical Industries Financial Results

Teva Pharmaceutical Industries reported Q3 2026 revenues of $4.4 billion, a 2% decrease year-over-year due to competition for its generic Revlimid, offset by 33% growth in its innovative brand portfolio. The company raised its full-year 2026 revenue outlook for key brands AUSTEDO, AJOVY, and UZEDY following strong quarterly performance and gross margin expansion.

Term
Q3 2026

“Teva’s Pivot to Growth strategy is delivering strong results, as evidenced by the 33% growth across our key innovative brands and the substantial expansion of our non-GAAP gross profit margin to its highest level in a decade. We are strengthening our neuroscience leadership with the launch of WELTRUZA™ and the strategic addition of BXCL-501, while our biosimilars business is set to achieve its 2027 revenue goal a year ahead of schedule.”

Richard Francis, Teva's President and CEO
8:09 AM ET 8-K
Financial Results Yum Brands Inc YUM

Yum Brands Financial Results

Yum! Brands reported Q3 2026 financial results, highlighted by a GAAP EPS of $5.92 which included a $1.7 billion pre-tax gain from the completed divestiture of the Pizza Hut brand. The company saw 7% unit growth at KFC and noted that Taco Bell U.S. has outpaced the QSR industry in same-store sales growth since the end of September.

Term
Q3 2026

“Yum! has entered its next chapter of growth, having completed the divestiture of Pizza Hut, with a sharper focus on our Raise the B.A.R. priorities. In support of those priorities, KFC delivered record Q3 global gross unit development and continues to scale its new global strategy reflecting the brand’s ambition of being the most modern chicken QSR.”

Chris Turner, CEO

“I’m also very pleased that, since the end of September, Taco Bell U.S. has been outpacing the QSR industry on same-store sales growth. Taco Bell will continue building on this momentum, with differentiated value and innovation that resonate across all consumer groups.”

Chris Turner, CEO
8:08 AM ET 8-K
Financial Results Henry Schein Inc HSIC

Henry Schein Financial Results

Henry Schein reported Q3 2026 financial results with total sales of $3.5 billion, representing 4.0% growth driven by strong U.S. dental merchandise volume. The company raised its full-year 2026 non-GAAP diluted EPS guidance to a range of $5.50 to $5.56, citing strong operating performance and net tariff refund benefits.

Term
Q3 2026

“We delivered another strong quarter that increases our confidence in the momentum we are building at Henry Schein. I am very pleased with the U.S. dental merchandise sales growth of 8.6% driven primarily by volume in a stable market and our 19% adjusted earnings per share growth.”

Fred Lowery, Chief Executive Officer of Henry Schein

“Our strategy is translating into stronger financial results. We are gaining share in key businesses, improving our portfolio mix, maintaining a disciplined approach to capital allocation, and realizing the benefits of our value creation initiatives.”

Fred Lowery, Chief Executive Officer of Henry Schein
8:08 AM ET 8-K
Financial Results Pfizer Inc PFE

Pfizer Financial Results

Pfizer reported Q3 2026 revenues of $16.6 billion, with 32% operational growth from launched and acquired products. The company raised its full-year 2026 revenue guidance to $62.0-$64.0 billion and appointed Cecile Guegan as its new Chief Financial Officer.

Term
Q3 2026

“Pfizer had another strong quarter with commercial momentum and disciplined execution while advancing our strategy for creating long-term shareholder value. Our obesity program continued to advance and recent milestones in oncology, immunology and vaccines further demonstrate the potential of our pipeline. With a robust slate of expected catalysts ahead, I believe we're well positioned to deliver meaningful new medicines for patients and lasting value in the years ahead.”

Dr. Albert Bourla, Chairman and CEO of Pfizer

“Our third-quarter results reflect strong commercial performance globally and continued operational discipline. This quarter, our non-COVID products delivered strong 7% operational revenue growth, and I’m particularly pleased with the 32% year-over-year operational revenue growth from our launched and acquired products. Today, we are raising our full-year 2026 Revenue and Adjusted diluted EPS guidance, reflecting our strong year-to-date performance and confidence in our business.”

Cecile Guegan, CFO and EVP of Pfizer
8:08 AM ET 8-K
Financial Results Marathon Petroleum Corp MPC

Marathon Petroleum Financial Results

Marathon Petroleum reported record third-quarter 2026 net income of $7.4 billion, driven by significantly higher market crack spreads and 100% crude capacity utilization. The company returned $3.3 billion to shareholders and announced a 10% increase in its quarterly dividend.

“Our value chain capabilities remain a defining advantage for us, capturing opportunities to enhance margins across dynamic market conditions. Strong planning, commercial, and operational execution generated significant cash flows, supporting high-return investments while delivering substantial returns to shareholders. MPLX’s durable growth and increasing cash flow to MPC delivers a differentiated value proposition.”

Maryann Mannen, Chairman, President and Chief Executive Officer
8:08 AM ET 8-K
Financial Results PJT Partners Inc. PJT

PJT Partners Financial Results

PJT Partners reported third quarter 2026 revenues of $385 million and record nine-month revenues of $1.29 billion. The company also announced an amendment to its $100 million revolving credit facility, extending the maturity date to November 2029. Despite a 14% year-over-year revenue decrease in the third quarter, the firm achieved record year-to-date pretax income and EPS.

Term
Q3 2026

“We continue to invest in our business to enhance our footprint, our capabilities, and our brand with the goal of better serving our clients and continuing to expand our market share. Our results continue to reflect this investment as we delivered record Revenues, record Pretax Income, and record EPS for the nine-month period. As before, we remain highly confident in our future growth prospects.”

Paul J. Taubman, Chairman and Chief Executive Officer
8:08 AM ET 8-K
Financial Results Mplx LP MPLX

Mplx Financial Results

MPLX LP reported third-quarter 2026 net income of $1.2 billion and adjusted EBITDA of $1.9 billion, representing a 5.3% year-over-year increase. The company announced a 12.5% increase in its quarterly distribution to $1.2111 per unit and highlighted the start of operations at its Harmon Creek III processing plant.

Term
Q3 2026

“Our third-quarter results reflect strong execution and the continued progression of our integrated natural gas and NGL value chain growth strategy. The durability of our cash flows enabled us to increase our quarterly distribution by 12.5% for the third consecutive year.”

Maryann Mannen, MPLX chairman, president and chief executive officer

“MPLX is positioned to meet global demand for U.S. energy and deliver mid-single digit adjusted EBITDA growth as utilization increases across our system and key growth projects enter service.”

Maryann Mannen, MPLX chairman, president and chief executive officer
8:08 AM ET 8-K
Financial Results Amneal Pharmaceuticals, Inc. AMRX

Amneal Pharmaceuticals Financial Results

Amneal Pharmaceuticals reported Q3 2026 net revenue of $863 million, a 10% increase year-over-year, driven by strong growth in biosimilars and specialty products. Despite the revenue growth, the company posted a GAAP net loss of $22 million due to acquisition and integration costs related to Kashiv. Consequently, Amneal raised its full-year 2026 guidance for revenue, adjusted EBITDA, and adjusted EPS.

Term
Q3 2026

“Amneal delivered another quarter of strong, broad-based performance, enabling us to increase our 2026 guidance once more. As we prepare to enter 2027, our financial performance is accelerating driven by a number of key catalysts and new launches, including Women’s Health patches, biosimilars, injectables such as lanreotide, CREXONT®, and BREKIYA® autoinjector.”

Chirag and Chintu Patel, Co-Founders and Co-Chief Executive Officers
8:07 AM ET 10-Q
Financial Results Compass Pathways plc CMPS

Compass Pathways Q3 2026 Results: Net Loss of $9.83M, Loss Narrows

COMPASS Pathways plc is advancing its COMP360 psilocybin treatment, currently in Phase 3 for treatment-resistant depression (TRD) and Phase 2b/3 for PTSD. The company reported 141,710,353 shares outstanding as of October 28, 2026, and maintains a loan agreement with Hercules Capital for up to $100 million to support its clinical and commercialization efforts.

Key figure
Net loss $9.83M
8:07 AM ET 8-K
Financial Results Athene Holding Ltd. ATH-PA

Athene Holding Financial Results

Athene Holding Ltd. reported its third quarter 2026 financial results as part of the earnings presentation issued by its parent company, Apollo Global Management. The results were impacted by unrealized mark-to-market losses in the Retirement Services segment due to higher interest rates, though the company maintained strong spread-related earnings.

Term
3 months
8:07 AM ET 8-K
Financial Results Cinemark Holdings, Inc. CNK

Cinemark Holdings Financial Results

Cinemark Holdings reported record-breaking third quarter 2026 results, with total revenue increasing 23.5% year-over-year to $1.1 billion. Net income grew 146% to $123 million, driven by strong box office momentum and record premium large format performance. The company achieved its highest-ever third quarter Adjusted EBITDA of $268 million with significant margin expansion.

Term
Q3 2026

“Following our record-breaking second quarter, we once again delivered exceptional Q3 results with worldwide revenue and Adjusted EBITDA reaching third quarter highs, and Adjusted EBITDA margin expanding 460 basis points year-over-year.”

Sean Gamble, Cinemark’s President and CEO

“Looking ahead, we remain highly confident in our long-term growth prospects and value proposition, supported by favorable consumer trends and content dynamics, as well as the distinct advantages we derive from our high-quality circuit, healthy balance sheet and differentiated competitive position.”

Sean Gamble, Cinemark’s President and CEO

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.